Intratumoural viral delivery improves glioblastoma survival
“Injecting a virus into a patient’s brain tumour” combined with immunotherapy improved glioblastoma survival outcomes in a clinical trial.
List view / Grid view
“Injecting a virus into a patient’s brain tumour” combined with immunotherapy improved glioblastoma survival outcomes in a clinical trial.
A first-in-human study showed a novel approach for delivering intrathecal and intravenous immunotherapy improved survival of melanoma patients with leptomeningeal disease (LMD).
Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…
New pre-clinical testing shows interleukin producing ‘drug factory’ implants can eliminate ovarian and colorectal cancer in mice.
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
The single-arm study showed that radiation therapy is an effective noninvasive alternative treatment for renal cell carcinoma (RCC).
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
President Trump has announced his intent to nominate Stephen Hahn as Commissioner of Food and Drugs at the Department of Health and Human Services.
A study has reported results of a clinical trial using CAR-T therapy where over half of the cancer patients were alive two years after the start...
Anti-CTLA-4 treatment triggers immune-suppressing EZH2 on T cells; clinical trial open...
Novel biomarker identified those with improved progression-free and overall survival...
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects...